Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656147 | 0.81 | KDM4E (0.35) | KDM4ECYP1A2PDE10APDGFRBPDGFRA | |
| SCHEMBL18869541 | 0.75 | PDE10A (0.46) | KDM4EPDE10ARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL9928483 | 0.72 | KDM4E (0.50) | KDM4ECYP1A2PDE10ARAB9AKMT2A | |
| SCHEMBL820776 | 0.70 | PDE10A (0.47) | KDM4ECYP1A2PDE10APDGFRBPDGFRA | |
| SCHEMBL5720367 | 0.69 | PDE10A (0.48) | KDM4EPDE10APDGFRBPDGFRARAB9A | |
| SCHEMBL24654876 | 0.68 | EGFR (0.35) | KDM4EPDE10AGPR3 | |
| SCHEMBL18661272 | 0.68 | PDE10A (0.44) | KDM4ECYP1A2PDE10APDGFRBPDGFRA | |
| SCHEMBL26837588 | 0.67 | PDE10A (0.41) | KDM4EPDE10ARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10737174 | 0.66 | KDM4E (0.46) | KDM4ECYP1A2RAB9AKMT2AGPR3 | |
| SCHEMBL5503119 | 0.66 | KDM4E (0.46) | KDM4ECYP1A2KMT2AGPR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885CYP1A2 540/4885PDE10A 594/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885CYP1A2 540/4885PDE10A 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.